• directSTIM™ Deep Brain Stimulation System Post-Market Clinical Follow-up Study on Essential Tremor

  NCT05795218

  TerminatedObservationalUpdated Aug 9, 2024
• Deep Brain Stimulation Effects in Essential Tremor

  NCT04581941

  CompletedObservationalUpdated Oct 9, 2024
• Algorithms for Programming DBS Systems for ET

  NCT03984643

  RecruitingInterventionalNot ApplicableUpdated Jan 27, 2026
• Physiology, Imaging and Modeling of Essential Tremor

  NCT03811405

  CompletedInterventionalNot ApplicableUpdated Jun 26, 2025
• Coordinated Reset Deep Brain Stimulation for Essential Tremor

  NCT05897775

  RecruitingInterventionalPhase 1Updated Jun 10, 2026
• Deep Brain Stimulation (DBS) Retrospective Outcomes Study

  NCT03664609

  RecruitingObservationalUpdated Aug 4, 2026

ClinicalTrials.gov ID

NCT04032470

Lead Sponsor

Boston Scientific CorporationINDUSTRY

Overall Status

Recruiting

Study Type

Observational

Enrollment

500Estimated

Last Update Posted

Aug 4, 2026Actual

Start Date

Oct 23, 2019Actual

Primary Completion Date

Dec 2029Estimated

Completion Date

Dec 2029Estimated

Official Title

Boston Scientific Registry of Deep Brain Stimulations for Treatment of Essential Tremor (ET):ET Registry

Brief Summary

To compile characteristics of real-world outcomes for Boston Scientific Corporation's commercially approved Deep Brain Stimulation (DBS) Systems, when used according to the applicable Directions for Use, for the treatment of Essential Tremor.

Detailed Description

To compile characteristics of real-world outcomes using Deep Brain Stimulation (DBS) for the treatment of Essential Tremor to add to the evidence available for treatment of ET.

• Essential Tremor

• Deep Brain Stimulation Systems (DBS)

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No data available

Eligibility Criteria

Inclusion Criteria:

• Meets criteria established in the locally applicable Directions for Use (DFU) for Essential Tremor
• Is at least 18 years old

Exclusion Criteria:

• Meets any contraindication in locally applicable Directions for Use

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Boston Scientific CorporationINDUSTRY

BSNClinicalTrials@bsci.com855-213-9890

BSNClinicalTrials@bsci.com855-213-9890

BSNClinicalTrials@bsci.com855-213-9890

BSNClinicalTrials@bsci.com855-213-9890